RNA-Targeted Small Molecules Market By Offering (mRNA Translation Modulators, RNA Splicing Modification, Direct RNA Targeting, Others); By Therapeutic Indication (Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Others); By End Users (Hospitals, Research Laboratories, Pharmaceutical and Biotechnology Companies, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
RNA is crucial in the control and expression of genes. It is an essential component in all biological systems as a central mediator of information transfer and gene regulation as it carries the instructions for protein synthesis. The importance of RNA structure in cellular processes and diseases has been revealed by recent advances in the understanding of RNA biochemistry, structure, and molecular biology. The process of using small-molecules to target RNA appears to be very similar to the more well-known process of targeting proteins. Small-molecules can change the way RNA functions by binding to pockets in these RNA structures. Small molecules target RNA in a wide range of diseases, including cancer, neurodegeneration, autoimmune, and inflammatory. Small molecules that target RNA are an emerging frontier in drug discovery and development because they open up a variety of new targets with novel approaches. Furthermore, an increasing number of cancer cases is expected to drive the growth of RNA-targeted small molecules market over the forecast period.
The market participants are undertaking strategic initiatives to collaborate with other companies, thereby contributing towards the growth of RNA-targeted small molecules market. For instance, Ribometrix, Inc., a biotechnology company, announced a significant collaboration with Genentech, a member of the Roche Group, in January 2021 to discover and develop novel RNA-targeted small molecule therapeutics against several targets. This collaboration with Genentech combines their leadership in RNA therapeutics with their global reach and breadth of expertise to accelerate the development of this important new class of medicines.
COVID-19 was declared a pandemic by the World Health Organization on March 11th, 2020 and since then it has caused millions of cases and a quarter million deaths. Pneumonia, lung injury, inflammation, and severe acute respiratory syndrome are clinical manifestations of this disease (SARS). Many pharmaceutical companies are actively involved in developing small molecule inhibitors to prevent virus entry into human hosts amidst the pandemic. Researchers from Goethe University in Germany discovered 69 small molecules that can bind to SARS-CoV-2 RNA segments, potentially stopping or slowing viral replication. The increased promise of innovation in drug discovery in the near future, showcases potential growth opportunities for market participants in the RNA-targeted small molecules market.
Global RNA-targeted small molecules market is estimated to register a CAGR of 6.1% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global RNA-Targeted Small Molecules Market Revenue & Forecast, (US$ Million), 2015 – 2030
Offering Outlook:
The global RNA-targeted small molecules market has been divided into mRNA translation modulators, RNA splicing modification, direct RNA targeting, and others. RNA splicing is the process of removing non-coding gene sequences (introns) from pre-mRNA and joining the protein-coding sequences (exons) together to allow mRNA to be translated into a protein. RNA splicing is frequently discovered during biochemical mechanisms of RNA splicing research or within the identification of genetic mutations in clinical practice and research. The overall function of alternative splicing is to boost the number of mRNAs expressed from the genome.
Therapeutic Indication Outlook:
Based on therapeutic indication, the global RNA-targeted small molecules market has been classified into lung fibrosis, cancer, neurogenerative diseases, autoimmune, inflammatory, and others. Among these segments, neurodegenerative diseases is anticipated to witness fastest growth over the forecast period. Neurodegenerative diseases afflict millions of people throughout the world. Alzheimer's disease and Parkinson's disease are amongst the most frequent neurodegenerative illnesses. According to a 2021 report from the Alzheimer's Disease Association, the number of Americans of the age 65 years and above with Alzheimer's disease were 6.2 million. The report highlights that the number can exceed to 13.8 million by 2030. Similarly, the number of people in the United States with Parkinson's disease is estimated to increase to 1.2 million by 2030, according to the data published by Parkinson's Foundation.
Investments in the direction of the therapeutic indication by market participants at large is further fueling the segment’s growth in the global RNA-targeted small molecules market. For instance, Servier, a global independent pharmaceutical group, and Nymirum, a specialist in RNA-targeted small molecules, announced that they have formed a strategic collaboration in July 2021 to identify and develop RNA-modulatory medications for the treatment of neurological illnesses. Nymirum will use its patented dart platform (dynamic atomic-resolution RNA targeting platform) to find innovative small molecule therapies for a variety of neurological targets under the terms of the collaboration agreement.
End Users Outlook:
Based on end users, the global RNA-targeted small molecules market has been classified into hospitals, research laboratories, pharmaceutical and biotechnology companies and others. The research laboratories segment is likely to be one of the most prominent growing segments over the forecast period due to increased spending on targeted therapies and the availability of new technology in these laboratories.
Region Outlook:
Asia Pacific is predicted to grow at the quickest rate in the global RNA-targeted small molecules market during the forecast period owing to rising healthcare spending for infrastructure improvements along with rise in research and development (R&D) activities across the region. Growing cases of cancer in the major economies in the region such as China and India is expected to drive the market growth. For Instance, According to the National Cancer Registry Programs, India's predicted cancer patient population for 2020 was 1,392,179, with lung, breast, mouth, cervix uteri, and tongue being the top five cancer sites.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of RNA-targeted small molecules market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global RNA-targeted small molecules market are:
- ACCENT THERAPEUTICS
- Anima Biotech Inc.
- Arrakis Therapeutics
- AstraZeneca
- Bayer AG
- Epics Therapeutics
- Expansion Therapeutics
- F. Hoffmann-La Roche Ltd
- H3 Biomedicine Inc.
- Novartis AG
- PTC Therapeutics
- Ribometrix
- SERVIER LABORATORIES
- Skyhawk Therapeutics, Inc.
- Other Market Participants
Global RNA-Targeted Small Molecules Market:
- By Offering
- mRNA Translation Modulators
- RNA Splicing Modification
- Direct RNA Targeting
- Others
- By Therapeutic Indication
- Lung Fibrosis
- Cancer
- Neurodegenerative Diseases
- Autoimmune
- Inflammatory
- Others
- By End Users
- Hospitals
- Research Laboratories
- Pharmaceutical and Biotechnology Companies
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market
Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2021
1.2.2. Base
Year: 2021
1.2.3. Forecast
Years: 2022 – 2030
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of RNA-Targeted Small Molecules Market
6. Market
Synopsis: RNA-Targeted Small Molecules
Market
7. RNA-Targeted
Small Molecules Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
RNA-Targeted Small Molecules Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: RNA-Targeted Small Molecules Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on RNA-Targeted Small Molecules Market
8. Global
RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global
RNA-Targeted Small Molecules Market Revenue (US$ Mn)
8.2. Global
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. mRNA
Translation Modulators
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 - 2021
8.2.1.3. Market
Forecast, 2022 - 2030
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 - 2021
8.2.1.5.1.2. Market
Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2021
8.2.1.5.2.2. Market
Forecast, 2022 - 2030
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2021
8.2.1.5.3.2. Market
Forecast, 2022 - 2030
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2021
8.2.1.5.4.2. Market
Forecast, 2022 - 2030
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 - 2021
8.2.1.5.5.2. Market
Forecast, 2022 - 2030
8.2.2. RNA
Splicing Modification
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 - 2021
8.2.2.3. Market
Forecast, 2022 - 2030
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 - 2021
8.2.2.5.1.2. Market
Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2021
8.2.2.5.2.2. Market
Forecast, 2022 - 2030
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2021
8.2.2.5.3.2. Market
Forecast, 2022 - 2030
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2021
8.2.2.5.4.2. Market
Forecast, 2022 - 2030
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 - 2021
8.2.2.5.5.2. Market
Forecast, 2022 - 2030
8.2.3. Direct
RNA Targeting
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 - 2021
8.2.3.3. Market
Forecast, 2022 - 2030
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 - 2021
8.2.3.5.1.2. Market
Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2021
8.2.3.5.2.2. Market
Forecast, 2022 - 2030
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2021
8.2.3.5.3.2. Market
Forecast, 2022 - 2030
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2021
8.2.3.5.4.2. Market
Forecast, 2022 - 2030
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 - 2021
8.2.3.5.5.2. Market
Forecast, 2022 - 2030
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 - 2021
8.2.4.3. Market
Forecast, 2022 - 2030
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 - 2021
8.2.4.5.1.2. Market
Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2021
8.2.4.5.2.2. Market
Forecast, 2022 - 2030
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2021
8.2.4.5.3.2. Market
Forecast, 2022 - 2030
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2021
8.2.4.5.4.2. Market
Forecast, 2022 - 2030
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 - 2021
8.2.4.5.5.2. Market
Forecast, 2022 - 2030
8.3. Key
Segment for Channeling Investments
8.3.1. By
Offering
9. Global
RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
9.2.1. Lung
Fibrosis
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 - 2021
9.2.1.3. Market
Forecast, 2022 - 2030
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 - 2021
9.2.1.5.1.2. Market
Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2021
9.2.1.5.2.2. Market
Forecast, 2022 - 2030
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2021
9.2.1.5.3.2. Market
Forecast, 2022 - 2030
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2021
9.2.1.5.4.2. Market
Forecast, 2022 - 2030
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 - 2021
9.2.1.5.5.2. Market
Forecast, 2022 - 2030
9.2.2. Cancer
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 - 2021
9.2.2.3. Market
Forecast, 2022 - 2030
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 - 2021
9.2.2.5.1.2. Market
Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2021
9.2.2.5.2.2. Market
Forecast, 2022 - 2030
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2021
9.2.2.5.3.2. Market
Forecast, 2022 - 2030
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2021
9.2.2.5.4.2. Market
Forecast, 2022 - 2030
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 - 2021
9.2.2.5.5.2. Market
Forecast, 2022 - 2030
9.2.3. Neurogenerative
Diseases
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 - 2021
9.2.3.3. Market
Forecast, 2022 - 2030
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 - 2021
9.2.3.5.1.2. Market
Forecast, 2022 - 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2021
9.2.3.5.2.2. Market
Forecast, 2022 - 2030
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2021
9.2.3.5.3.2. Market
Forecast, 2022 - 2030
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2021
9.2.3.5.4.2. Market
Forecast, 2022 - 2030
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 - 2021
9.2.3.5.5.2. Market
Forecast, 2022 - 2030
9.2.4. Autoimmune
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 - 2021
9.2.4.3. Market
Forecast, 2022 - 2030
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 - 2021
9.2.4.5.1.2. Market
Forecast, 2022 - 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2021
9.2.4.5.2.2. Market
Forecast, 2022 - 2030
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2021
9.2.4.5.3.2. Market
Forecast, 2022 - 2030
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2021
9.2.4.5.4.2. Market
Forecast, 2022 - 2030
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 - 2021
9.2.4.5.5.2. Market
Forecast, 2022 - 2030
9.2.5. Inflammatory
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 - 2021
9.2.5.3. Market
Forecast, 2022 - 2030
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 - 2021
9.2.5.5.1.2. Market
Forecast, 2022 - 2030
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2021
9.2.5.5.2.2. Market
Forecast, 2022 - 2030
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2021
9.2.5.5.3.2. Market
Forecast, 2022 - 2030
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2021
9.2.5.5.4.2. Market
Forecast, 2022 - 2030
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 - 2021
9.2.5.5.5.2. Market
Forecast, 2022 - 2030
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 - 2021
9.2.6.3. Market
Forecast, 2022 - 2030
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 - 2021
9.2.6.5.1.2. Market
Forecast, 2022 - 2030
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2021
9.2.6.5.2.2. Market
Forecast, 2022 - 2030
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2021
9.2.6.5.3.2. Market
Forecast, 2022 - 2030
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2021
9.2.6.5.4.2. Market
Forecast, 2022 - 2030
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 - 2021
9.2.6.5.5.2. Market
Forecast, 2022 - 2030
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapeutic Indication
10. Global
RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
10.2.1. Hospitals
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 - 2021
10.2.1.3. Market
Forecast, 2022 - 2030
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 - 2021
10.2.1.5.1.2. Market
Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2021
10.2.1.5.2.2. Market
Forecast, 2022 - 2030
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2021
10.2.1.5.3.2. Market
Forecast, 2022 - 2030
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2021
10.2.1.5.4.2. Market
Forecast, 2022 - 2030
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 - 2021
10.2.1.5.5.2. Market
Forecast, 2022 - 2030
10.2.2. Research
Laboratories
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 - 2021
10.2.2.3. Market
Forecast, 2022 - 2030
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 - 2021
10.2.2.5.1.2. Market
Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2021
10.2.2.5.2.2. Market
Forecast, 2022 - 2030
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2021
10.2.2.5.3.2. Market
Forecast, 2022 - 2030
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2021
10.2.2.5.4.2. Market
Forecast, 2022 - 2030
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 - 2021
10.2.2.5.5.2. Market
Forecast, 2022 - 2030
10.2.3. Pharmaceutical
and Biotechnology Companies
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 - 2021
10.2.3.3. Market
Forecast, 2022 - 2030
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 - 2021
10.2.3.5.1.2. Market
Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2021
10.2.3.5.2.2. Market
Forecast, 2022 - 2030
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2021
10.2.3.5.3.2. Market
Forecast, 2022 - 2030
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2021
10.2.3.5.4.2. Market
Forecast, 2022 - 2030
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 - 2021
10.2.3.5.5.2. Market
Forecast, 2022 - 2030
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 - 2021
10.2.4.3. Market
Forecast, 2022 - 2030
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 - 2021
10.2.4.5.1.2. Market
Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2021
10.2.4.5.2.2. Market
Forecast, 2022 - 2030
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2021
10.2.4.5.3.2. Market
Forecast, 2022 - 2030
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2021
10.2.4.5.4.2. Market
Forecast, 2022 - 2030
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 - 2021
10.2.4.5.5.2. Market
Forecast, 2022 - 2030
10.3. Key
Segment for Channeling Investments
10.3.1. By End
Users
11. North
America RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North
America RNA-Targeted Small Molecules Market Revenue (US$ Mn)
11.2. North
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
11.2.1. mRNA
Translation Modulators
11.2.2. RNA
Splicing Modification
11.2.3. Direct
RNA Targeting
11.2.4. Others
11.3. North
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
11.3.1. Lung
Fibrosis
11.3.2. Cancer
11.3.3. Neurogenerative
Diseases
11.3.4. Autoimmune
11.3.5. Inflammatory
11.3.6. Others
11.4. North
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
11.4.1. Hospitals
11.4.2. Research
Laboratories
11.4.3. Pharmaceutical
and Biotechnology Companies
11.4.4. Others
11.5. North
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Country
11.5.1. U.S
11.5.1.1. U.S
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.1.1.1. mRNA
Translation Modulators
11.5.1.1.2. RNA
Splicing Modification
11.5.1.1.3. Direct
RNA Targeting
11.5.1.1.4. Others
11.5.1.2. U.S
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
11.5.1.2.1. Lung
Fibrosis
11.5.1.2.2. Cancer
11.5.1.2.3. Neurogenerative
Diseases
11.5.1.2.4. Autoimmune
11.5.1.2.5. Inflammatory
11.5.1.2.6. Others
11.5.1.3. U.S
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
11.5.1.3.1. Hospitals
11.5.1.3.2. Research
Laboratories
11.5.1.3.3. Pharmaceutical
and Biotechnology Companies
11.5.1.3.4. Others
11.5.2. Canada
11.5.2.1. Canada
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.2.1.1. mRNA
Translation Modulators
11.5.2.1.2. RNA
Splicing Modification
11.5.2.1.3. Direct
RNA Targeting
11.5.2.1.4. Others
11.5.2.2. Canada
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
11.5.2.2.1. Lung
Fibrosis
11.5.2.2.2. Cancer
11.5.2.2.3. Neurogenerative
Diseases
11.5.2.2.4. Autoimmune
11.5.2.2.5. Inflammatory
11.5.2.2.6. Others
11.5.2.3. Canada
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
11.5.2.3.1. Hospitals
11.5.2.3.2. Research
Laboratories
11.5.2.3.3. Pharmaceutical
and Biotechnology Companies
11.5.2.3.4. Others
11.5.3. Mexico
11.5.3.1. Mexico
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.3.1.1. mRNA
Translation Modulators
11.5.3.1.2. RNA
Splicing Modification
11.5.3.1.3. Direct
RNA Targeting
11.5.3.1.4. Others
11.5.3.2. Mexico
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
11.5.3.2.1. Lung
Fibrosis
11.5.3.2.2. Cancer
11.5.3.2.3. Neurogenerative
Diseases
11.5.3.2.4. Autoimmune
11.5.3.2.5. Inflammatory
11.5.3.2.6. Others
11.5.3.3. Mexico
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
11.5.3.3.1. Hospitals
11.5.3.3.2. Research
Laboratories
11.5.3.3.3. Pharmaceutical
and Biotechnology Companies
11.5.3.3.4. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Offering
11.5.4.1.1. mRNA
Translation Modulators
11.5.4.1.2. RNA
Splicing Modification
11.5.4.1.3. Direct
RNA Targeting
11.5.4.1.4. Others
11.5.4.2. Rest
of North America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
11.5.4.2.1. Lung
Fibrosis
11.5.4.2.2. Cancer
11.5.4.2.3. Neurogenerative
Diseases
11.5.4.2.4. Autoimmune
11.5.4.2.5. Inflammatory
11.5.4.2.6. Others
11.5.4.3. Rest
of North America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By End Users
11.5.4.3.1. Hospitals
11.5.4.3.2. Research
Laboratories
11.5.4.3.3. Pharmaceutical
and Biotechnology Companies
11.5.4.3.4. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Offering
11.6.3. By
Therapeutic Indication
11.6.4. By End
Users
12. Europe
RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe RNA-Targeted
Small Molecules Market Revenue (US$ Mn)
12.2. Europe
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. mRNA
Translation Modulators
12.2.2. RNA
Splicing Modification
12.2.3. Direct
RNA Targeting
12.2.4. Others
12.3. Europe
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.3.1. Lung
Fibrosis
12.3.2. Cancer
12.3.3. Neurogenerative
Diseases
12.3.4. Autoimmune
12.3.5. Inflammatory
12.3.6. Others
12.4. Europe
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.4.1. Hospitals
12.4.2. Research
Laboratories
12.4.3. Pharmaceutical
and Biotechnology Companies
12.4.4. Others
12.5. Europe
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.1.1.1. mRNA
Translation Modulators
12.5.1.1.2. RNA
Splicing Modification
12.5.1.1.3. Direct
RNA Targeting
12.5.1.1.4. Others
12.5.1.2. France
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.1.2.1. Lung
Fibrosis
12.5.1.2.2. Cancer
12.5.1.2.3. Neurogenerative
Diseases
12.5.1.2.4. Autoimmune
12.5.1.2.5. Inflammatory
12.5.1.2.6. Others
12.5.1.3. France
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.1.3.1. Hospitals
12.5.1.3.2. Research
Laboratories
12.5.1.3.3. Pharmaceutical
and Biotechnology Companies
12.5.1.3.4. Others
12.5.2. The UK
12.5.2.1. The
UK RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.2.1.1. mRNA
Translation Modulators
12.5.2.1.2. RNA
Splicing Modification
12.5.2.1.3. Direct
RNA Targeting
12.5.2.1.4. Others
12.5.2.2. The
UK RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.2.2.1. Lung
Fibrosis
12.5.2.2.2. Cancer
12.5.2.2.3. Neurogenerative
Diseases
12.5.2.2.4. Autoimmune
12.5.2.2.5. Inflammatory
12.5.2.2.6. Others
12.5.2.3. The
UK RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.2.3.1. Hospitals
12.5.2.3.2. Research
Laboratories
12.5.2.3.3. Pharmaceutical
and Biotechnology Companies
12.5.2.3.4. Others
12.5.3. Spain
12.5.3.1. Spain
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.3.1.1. mRNA
Translation Modulators
12.5.3.1.2. RNA
Splicing Modification
12.5.3.1.3. Direct
RNA Targeting
12.5.3.1.4. Others
12.5.3.2. Spain
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.3.2.1. Lung
Fibrosis
12.5.3.2.2. Cancer
12.5.3.2.3. Neurogenerative
Diseases
12.5.3.2.4. Autoimmune
12.5.3.2.5. Inflammatory
12.5.3.2.6. Others
12.5.3.3. Spain
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.3.3.1. Hospitals
12.5.3.3.2. Research
Laboratories
12.5.3.3.3. Pharmaceutical
and Biotechnology Companies
12.5.3.3.4. Others
12.5.4. Germany
12.5.4.1. Germany
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.4.1.1. mRNA
Translation Modulators
12.5.4.1.2. RNA
Splicing Modification
12.5.4.1.3. Direct
RNA Targeting
12.5.4.1.4. Others
12.5.4.2. Germany
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.4.2.1. Lung
Fibrosis
12.5.4.2.2. Cancer
12.5.4.2.3. Neurogenerative
Diseases
12.5.4.2.4. Autoimmune
12.5.4.2.5. Inflammatory
12.5.4.2.6. Others
12.5.4.3. Germany
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.4.3.1. Hospitals
12.5.4.3.2. Research
Laboratories
12.5.4.3.3. Pharmaceutical
and Biotechnology Companies
12.5.4.3.4. Others
12.5.5. Italy
12.5.5.1. Italy
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.5.1.1. mRNA
Translation Modulators
12.5.5.1.2. RNA
Splicing Modification
12.5.5.1.3. Direct
RNA Targeting
12.5.5.1.4. Others
12.5.5.2. Italy
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.5.2.1. Lung
Fibrosis
12.5.5.2.2. Cancer
12.5.5.2.3. Neurogenerative
Diseases
12.5.5.2.4. Autoimmune
12.5.5.2.5. Inflammatory
12.5.5.2.6. Others
12.5.5.3. Italy
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.5.3.1. Hospitals
12.5.5.3.2. Research
Laboratories
12.5.5.3.3. Pharmaceutical
and Biotechnology Companies
12.5.5.3.4. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Offering
12.5.6.1.1. mRNA
Translation Modulators
12.5.6.1.2. RNA
Splicing Modification
12.5.6.1.3. Direct
RNA Targeting
12.5.6.1.4. Others
12.5.6.2. Nordic
Countries RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
12.5.6.2.1. Lung
Fibrosis
12.5.6.2.2. Cancer
12.5.6.2.3. Neurogenerative
Diseases
12.5.6.2.4. Autoimmune
12.5.6.2.5. Inflammatory
12.5.6.2.6. Others
12.5.6.3. Nordic
Countries RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.6.3.1. Hospitals
12.5.6.3.2. Research
Laboratories
12.5.6.3.3. Pharmaceutical
and Biotechnology Companies
12.5.6.3.4. Others
12.5.6.4. Nordic
Countries RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.7.1.1. mRNA
Translation Modulators
12.5.7.1.2. RNA
Splicing Modification
12.5.7.1.3. Direct
RNA Targeting
12.5.7.1.4. Others
12.5.7.2. Benelux
Union RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.5.7.2.1. Lung
Fibrosis
12.5.7.2.2. Cancer
12.5.7.2.3. Neurogenerative
Diseases
12.5.7.2.4. Autoimmune
12.5.7.2.5. Inflammatory
12.5.7.2.6. Others
12.5.7.3. Benelux
Union RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
12.5.7.3.1. Hospitals
12.5.7.3.2. Research
Laboratories
12.5.7.3.3. Pharmaceutical
and Biotechnology Companies
12.5.7.3.4. Others
12.5.7.4. Benelux
Union RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Offering
12.5.8.1.1. mRNA
Translation Modulators
12.5.8.1.2. RNA
Splicing Modification
12.5.8.1.3. Direct
RNA Targeting
12.5.8.1.4. Others
12.5.8.2. Rest
of Europe RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
12.5.8.2.1. Lung
Fibrosis
12.5.8.2.2. Cancer
12.5.8.2.3. Neurogenerative
Diseases
12.5.8.2.4. Autoimmune
12.5.8.2.5. Inflammatory
12.5.8.2.6. Others
12.5.8.3. Rest
of Europe RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts,
By End Users
12.5.8.3.1. Hospitals
12.5.8.3.2. Research
Laboratories
12.5.8.3.3. Pharmaceutical
and Biotechnology Companies
12.5.8.3.4. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Offering
12.6.3. By
Therapeutic Indication
12.6.4. By End
Users
13. Asia
Pacific RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia
Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn)
13.2. Asia
Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
13.2.1. mRNA
Translation Modulators
13.2.2. RNA
Splicing Modification
13.2.3. Direct
RNA Targeting
13.2.4. Others
13.3. Asia
Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.3.1. Lung
Fibrosis
13.3.2. Cancer
13.3.3. Neurogenerative
Diseases
13.3.4. Autoimmune
13.3.5. Inflammatory
13.3.6. Others
13.4. Asia
Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
13.4.1. Hospitals
13.4.2. Research
Laboratories
13.4.3. Pharmaceutical
and Biotechnology Companies
13.4.4. Others
13.5. Asia
Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.1. China
13.5.1.1. China
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.1.1.1. mRNA
Translation Modulators
13.5.1.1.2. RNA
Splicing Modification
13.5.1.1.3. Direct
RNA Targeting
13.5.1.1.4. Others
13.5.1.2. China
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.1.2.1. Lung
Fibrosis
13.5.1.2.2. Cancer
13.5.1.2.3. Neurogenerative
Diseases
13.5.1.2.4. Autoimmune
13.5.1.2.5. Inflammatory
13.5.1.2.6. Others
13.5.1.3. China
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.1.3.1. Hospitals
13.5.1.3.2. Research
Laboratories
13.5.1.3.3. Pharmaceutical
and Biotechnology Companies
13.5.1.3.4. Others
13.5.2. Japan
13.5.2.1. Japan
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.2.1.1. mRNA
Translation Modulators
13.5.2.1.2. RNA
Splicing Modification
13.5.2.1.3. Direct
RNA Targeting
13.5.2.1.4. Others
13.5.2.2. Japan
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.2.2.1. Lung
Fibrosis
13.5.2.2.2. Cancer
13.5.2.2.3. Neurogenerative
Diseases
13.5.2.2.4. Autoimmune
13.5.2.2.5. Inflammatory
13.5.2.2.6. Others
13.5.2.3. Japan
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.2.3.1. Hospitals
13.5.2.3.2. Research
Laboratories
13.5.2.3.3. Pharmaceutical
and Biotechnology Companies
13.5.2.3.4. Others
13.5.3. India
13.5.3.1. India
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.3.1.1. mRNA
Translation Modulators
13.5.3.1.2. RNA
Splicing Modification
13.5.3.1.3. Direct
RNA Targeting
13.5.3.1.4. Others
13.5.3.2. India
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
13.5.3.2.1. Lung
Fibrosis
13.5.3.2.2. Cancer
13.5.3.2.3. Neurogenerative
Diseases
13.5.3.2.4. Autoimmune
13.5.3.2.5. Inflammatory
13.5.3.2.6. Others
13.5.3.3. India
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.3.3.1. Hospitals
13.5.3.3.2. Research
Laboratories
13.5.3.3.3. Pharmaceutical
and Biotechnology Companies
13.5.3.3.4. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.4.1.1. mRNA
Translation Modulators
13.5.4.1.2. RNA
Splicing Modification
13.5.4.1.3. Direct
RNA Targeting
13.5.4.1.4. Others
13.5.4.2. New
Zealand RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.4.2.1. Lung
Fibrosis
13.5.4.2.2. Cancer
13.5.4.2.3. Neurogenerative
Diseases
13.5.4.2.4. Autoimmune
13.5.4.2.5. Inflammatory
13.5.4.2.6. Others
13.5.4.3. New
Zealand RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
13.5.4.3.1. Hospitals
13.5.4.3.2. Research
Laboratories
13.5.4.3.3. Pharmaceutical
and Biotechnology Companies
13.5.4.3.4. Others
13.5.5. Australia
13.5.5.1. Australia
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.5.1.1. mRNA
Translation Modulators
13.5.5.1.2. RNA
Splicing Modification
13.5.5.1.3. Direct
RNA Targeting
13.5.5.1.4. Others
13.5.5.2. Australia
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.5.2.1. Lung
Fibrosis
13.5.5.2.2. Cancer
13.5.5.2.3. Neurogenerative
Diseases
13.5.5.2.4. Autoimmune
13.5.5.2.5. Inflammatory
13.5.5.2.6. Others
13.5.5.3. Australia
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.5.3.1. Hospitals
13.5.5.3.2. Research
Laboratories
13.5.5.3.3. Pharmaceutical
and Biotechnology Companies
13.5.5.3.4. Others
13.5.6. South
Korea
13.5.6.1. South
Korea RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.6.1.1. mRNA
Translation Modulators
13.5.6.1.2. RNA
Splicing Modification
13.5.6.1.3. Direct
RNA Targeting
13.5.6.1.4. Others
13.5.6.2. South
Korea RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.6.2.1. Lung
Fibrosis
13.5.6.2.2. Cancer
13.5.6.2.3. Neurogenerative
Diseases
13.5.6.2.4. Autoimmune
13.5.6.2.5. Inflammatory
13.5.6.2.6. Others
13.5.6.3. South
Korea RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
13.5.6.3.1. Hospitals
13.5.6.3.2. Research
Laboratories
13.5.6.3.3. Pharmaceutical
and Biotechnology Companies
13.5.6.3.4. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.7.1.1. mRNA
Translation Modulators
13.5.7.1.2. RNA
Splicing Modification
13.5.7.1.3. Direct
RNA Targeting
13.5.7.1.4. Others
13.5.7.2. Southeast
Asia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
13.5.7.2.1. Lung
Fibrosis
13.5.7.2.2. Cancer
13.5.7.2.3. Neurogenerative
Diseases
13.5.7.2.4. Autoimmune
13.5.7.2.5. Inflammatory
13.5.7.2.6. Others
13.5.7.3. Southeast
Asia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
13.5.7.3.1. Hospitals
13.5.7.3.2. Research
Laboratories
13.5.7.3.3. Pharmaceutical
and Biotechnology Companies
13.5.7.3.4. Others
13.5.7.4. Southeast
Asia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Offering
13.5.8.1.1. mRNA
Translation Modulators
13.5.8.1.2. RNA
Splicing Modification
13.5.8.1.3. Direct
RNA Targeting
13.5.8.1.4. Others
13.5.8.2. Rest
of Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.5.8.2.1. Lung
Fibrosis
13.5.8.2.2. Cancer
13.5.8.2.3. Neurogenerative
Diseases
13.5.8.2.4. Autoimmune
13.5.8.2.5. Inflammatory
13.5.8.2.6. Others
13.5.8.3. Rest
of Asia Pacific RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By End Users
13.5.8.3.1. Hospitals
13.5.8.3.2. Research
Laboratories
13.5.8.3.3. Pharmaceutical
and Biotechnology Companies
13.5.8.3.4. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Offering
13.6.3. By
Therapeutic Indication
13.6.4. By End
Users
14. Middle
East and Africa RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022
- 2030
14.1. Overview
14.1.1. Middle
East and Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn)
14.2. Middle
East and Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Offering
14.2.1. mRNA
Translation Modulators
14.2.2. RNA
Splicing Modification
14.2.3. Direct
RNA Targeting
14.2.4. Others
14.3. Middle
East and Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.3.1. Lung
Fibrosis
14.3.2. Cancer
14.3.3. Neurogenerative
Diseases
14.3.4. Autoimmune
14.3.5. Inflammatory
14.3.6. Others
14.4. Middle
East and Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By End Users
14.4.1. Hospitals
14.4.2. Research
Laboratories
14.4.3. Pharmaceutical
and Biotechnology Companies
14.4.4. Others
14.5. Middle
East and Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
14.5.1.1.1. mRNA
Translation Modulators
14.5.1.1.2. RNA
Splicing Modification
14.5.1.1.3. Direct
RNA Targeting
14.5.1.1.4. Others
14.5.1.2. Saudi
Arabia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.5.1.2.1. Lung
Fibrosis
14.5.1.2.2. Cancer
14.5.1.2.3. Neurogenerative
Diseases
14.5.1.2.4. Autoimmune
14.5.1.2.5. Inflammatory
14.5.1.2.6. Others
14.5.1.3. Saudi
Arabia RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
14.5.1.3.1. Hospitals
14.5.1.3.2. Research
Laboratories
14.5.1.3.3. Pharmaceutical
and Biotechnology Companies
14.5.1.3.4. Others
14.5.2. UAE
14.5.2.1. UAE
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.2.1.1. mRNA
Translation Modulators
14.5.2.1.2. RNA
Splicing Modification
14.5.2.1.3. Direct
RNA Targeting
14.5.2.1.4. Others
14.5.2.2. UAE
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.5.2.2.1. Lung
Fibrosis
14.5.2.2.2. Cancer
14.5.2.2.3. Neurogenerative
Diseases
14.5.2.2.4. Autoimmune
14.5.2.2.5. Inflammatory
14.5.2.2.6. Others
14.5.2.3. UAE
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.2.3.1. Hospitals
14.5.2.3.2. Research
Laboratories
14.5.2.3.3. Pharmaceutical
and Biotechnology Companies
14.5.2.3.4. Others
14.5.3. Egypt
14.5.3.1. Egypt
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.3.1.1. mRNA
Translation Modulators
14.5.3.1.2. RNA
Splicing Modification
14.5.3.1.3. Direct
RNA Targeting
14.5.3.1.4. Others
14.5.3.2. Egypt
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.5.3.2.1. Lung
Fibrosis
14.5.3.2.2. Cancer
14.5.3.2.3. Neurogenerative
Diseases
14.5.3.2.4. Autoimmune
14.5.3.2.5. Inflammatory
14.5.3.2.6. Others
14.5.3.3. Egypt
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.3.3.1. Hospitals
14.5.3.3.2. Research
Laboratories
14.5.3.3.3. Pharmaceutical
and Biotechnology Companies
14.5.3.3.4. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.4.1.1. mRNA
Translation Modulators
14.5.4.1.2. RNA
Splicing Modification
14.5.4.1.3. Direct
RNA Targeting
14.5.4.1.4. Others
14.5.4.2. Kuwait
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.5.4.2.1. Lung
Fibrosis
14.5.4.2.2. Cancer
14.5.4.2.3. Neurogenerative
Diseases
14.5.4.2.4. Autoimmune
14.5.4.2.5. Inflammatory
14.5.4.2.6. Others
14.5.4.3. Kuwait
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.4.3.1. Hospitals
14.5.4.3.2. Research
Laboratories
14.5.4.3.3. Pharmaceutical
and Biotechnology Companies
14.5.4.3.4. Others
14.5.5. South
Africa
14.5.5.1. South
Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
14.5.5.1.1. mRNA
Translation Modulators
14.5.5.1.2. RNA
Splicing Modification
14.5.5.1.3. Direct
RNA Targeting
14.5.5.1.4. Others
14.5.5.2. South
Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
14.5.5.2.1. Lung
Fibrosis
14.5.5.2.2. Cancer
14.5.5.2.3. Neurogenerative
Diseases
14.5.5.2.4. Autoimmune
14.5.5.2.5. Inflammatory
14.5.5.2.6. Others
14.5.5.3. South
Africa RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
14.5.5.3.1. Hospitals
14.5.5.3.2. Research
Laboratories
14.5.5.3.3. Pharmaceutical
and Biotechnology Companies
14.5.5.3.4. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$
Mn) and Forecasts, By Offering
14.5.6.1.1. mRNA
Translation Modulators
14.5.6.1.2. RNA
Splicing Modification
14.5.6.1.3. Direct
RNA Targeting
14.5.6.1.4. Others
14.5.6.2. Rest
of Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
14.5.6.2.1. Lung
Fibrosis
14.5.6.2.2. Cancer
14.5.6.2.3. Neurogenerative
Diseases
14.5.6.2.4. Autoimmune
14.5.6.2.5. Inflammatory
14.5.6.2.6. Others
14.5.6.3. Rest
of Middle East & Africa RNA-Targeted Small Molecules Market Revenue (US$
Mn) and Forecasts, By End Users
14.5.6.3.1. Hospitals
14.5.6.3.2. Research
Laboratories
14.5.6.3.3. Pharmaceutical
and Biotechnology Companies
14.5.6.3.4. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Offering
14.6.3. By
Therapeutic Indication
14.6.4. By End
Users
15. Latin
America RNA-Targeted Small Molecules Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin
America RNA-Targeted Small Molecules Market Revenue (US$ Mn)
15.2. Latin
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Offering
15.2.1. mRNA
Translation Modulators
15.2.2. RNA
Splicing Modification
15.2.3. Direct
RNA Targeting
15.2.4. Others
15.3. Latin
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.3.1. Lung
Fibrosis
15.3.2. Cancer
15.3.3. Neurogenerative
Diseases
15.3.4. Autoimmune
15.3.5. Inflammatory
15.3.6. Others
15.4. Latin
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
End Users
15.4.1. Hospitals
15.4.2. Research
Laboratories
15.4.3. Pharmaceutical
and Biotechnology Companies
15.4.4. Others
15.5. Latin
America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Country
15.5.1. Brazil
15.5.1.1. Brazil
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.1.1.1. mRNA
Translation Modulators
15.5.1.1.2. RNA
Splicing Modification
15.5.1.1.3. Direct
RNA Targeting
15.5.1.1.4. Others
15.5.1.2. Brazil
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.5.1.2.1. Lung
Fibrosis
15.5.1.2.2. Cancer
15.5.1.2.3. Neurogenerative
Diseases
15.5.1.2.4. Autoimmune
15.5.1.2.5. Inflammatory
15.5.1.2.6. Others
15.5.1.3. Brazil
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
15.5.1.3.1. Hospitals
15.5.1.3.2. Research
Laboratories
15.5.1.3.3. Pharmaceutical
and Biotechnology Companies
15.5.1.3.4. Others
15.5.2. Argentina
15.5.2.1. Argentina
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.2.1.1. mRNA
Translation Modulators
15.5.2.1.2. RNA
Splicing Modification
15.5.2.1.3. Direct
RNA Targeting
15.5.2.1.4. Others
15.5.2.2. Argentina
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
15.5.2.2.1. Lung
Fibrosis
15.5.2.2.2. Cancer
15.5.2.2.3. Neurogenerative
Diseases
15.5.2.2.4. Autoimmune
15.5.2.2.5. Inflammatory
15.5.2.2.6. Others
15.5.2.3. Argentina
RNA-Targeted Small Molecules Market Revenue (US$ Mn) and Forecasts, By End
Users
15.5.2.3.1. Hospitals
15.5.2.3.2. Research
Laboratories
15.5.2.3.3. Pharmaceutical
and Biotechnology Companies
15.5.2.3.4. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Offering
15.5.3.1.1. mRNA
Translation Modulators
15.5.3.1.2. RNA
Splicing Modification
15.5.3.1.3. Direct
RNA Targeting
15.5.3.1.4. Others
15.5.3.2. Rest
of Latin America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.5.3.2.1. Lung
Fibrosis
15.5.3.2.2. Cancer
15.5.3.2.3. Neurogenerative
Diseases
15.5.3.2.4. Autoimmune
15.5.3.2.5. Inflammatory
15.5.3.2.6. Others
15.5.3.3. Rest
of Latin America RNA-Targeted Small Molecules Market Revenue (US$ Mn) and
Forecasts, By End Users
15.5.3.3.1. Hospitals
15.5.3.3.2. Research
Laboratories
15.5.3.3.3. Pharmaceutical
and Biotechnology Companies
15.5.3.3.4. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Offering
15.6.3. By
Therapeutic Indication
15.6.4. By End
Users
16. Competitive
Benchmarking
16.1. Market
Share Analysis, 2021
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player
Profiles
17.1. ACCENT
THERAPEUTICS
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Anima
Biotech Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business Strategies
17.3. Arrakis Therapeutics
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. AstraZeneca
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Bayer AG
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Epics Therapeutics
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Expansion Therapeutics
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. F. Hoffmann-La Roche Ltd
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. H3 Biomedicine Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Novartis AG
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. PTC Therapeutics
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Ribometrix
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. Skyhawk Therapeutics, Inc.
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. Other Market Participants
18. Key
Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
